In November 2015, to meet ongoing client demand, Almac Group announced the expansion of its pharmaceutical development and manufacturing services with the acquisition of a significant proportion of the 70-acre Charnwood Campus in Loughborough, England — a world-class science, technology and enterprise park.
Since the announcement the facilities have undergone significant investment both in building enhancements and the installation and validation of new processing and analytical technology.
This successful MHRA inspection provides Almac Pharma Services with the necessary licenses to develop, manufacture and pack non-potent and potent, solid oral drug products for clinical trials and commercial supply at the Charnwood site, with the new facility complementing the existing development & GMP services offered from the company’s Craigavon NI Headquarters.
Trevor Clarke, Global Head of Quality Systems, said: “This positive endorsement by the MHRA provides our clients with increased capacity governed by the same pharmaceutical quality system, which they are already familiar with at our existing sites in Craigavon, Northern Ireland and Audubon, Pennsylvania.”
